title: Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.
abstract: Neutrophils are the most abundant circulating FcR-expressing WBCs with potent cytotoxic ability. Currently, they are recognized as promising effector cells for Ab-mediated immunotherapy of cancer, because their capacity to kill tumor cells is greatly enhanced by tumor Ag-specific mAbs. The FcαRI represents the most potent FcR on neutrophils for induction of Ab-mediated tumor cell killing. However, the mechanisms of cell death that are induced are poorly understood. Because these mechanisms can be used for modulation of anticancer treatment, we investigated the tumor cell death induced by neutrophil-mediated Ab-dependent killing via FcαRI. Human mammary carcinoma cells were efficiently killed when incubated with human neutrophils and tumor-specific FcαRI bispecific or IgA Abs. Interestingly, we observed characteristics of autophagy such as autophagic structures by electron microscopy and LC3B(+) autophagosomes in different human epithelial carcinoma cells, which resulted in tumor cell death. To a lesser extent, necrotic features, such as cellular membrane breakdown and spillage of intracellular content, were found. By contrast, apoptotic features including fragmented nuclei, Annexin V-positivity, and presence of cleaved caspase-3 were not observed. These findings indicate that neutrophils mainly facilitate autophagy to induce tumor cell death rather than the more commonly recognized apoptotic cell death mechanisms induced by NK cells or cytotoxic T cells. This knowledge not only reveals the type of tumor cell death induced in neutrophil-mediated, Ab-dependent cellular cytotoxicity, but importantly opens up additional perspectives for modulation of anticancer therapy in, for example, apoptosis-resistant tumor cells.
authors.affiliation: Department of Molecular Cell Biology and Immunology, VU University Medical Center, 1081 BT Amsterdam, The Netherlands.
authors.forename: Jantine E
authors.initials: JE
authors.lastname: Bakema
authors.forename: Sonja H
authors.initials: SH
authors.lastname: Ganzevles
authors.forename: Donna M
authors.initials: DM
authors.lastname: Fluitsma
authors.forename: Marco W
authors.initials: MW
authors.lastname: Schilham
authors.forename: Robert H J
authors.initials: RH
authors.lastname: Beelen
authors.forename: Thomas
authors.initials: T
authors.lastname: Valerius
authors.forename: Stefan
authors.initials: S
authors.lastname: Lohse
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Glennie
authors.forename: Jan Paul
authors.initials: JP
authors.lastname: Medema
authors.forename: Marjolein
authors.initials: M
authors.lastname: van Egmond
mesh_terms: D018033:Antibodies, Bispecific / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D017209:Apoptosis / Q000276:immunology; D001343:Autophagy / Q000276:immunology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D018920:Coculture Techniques; D018390:Gene Targeting / Q000379:methods*; D006801:Humans; D007070:Immunoglobulin A / Q000502:physiology; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D011961:Receptors, Fc / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
chemical_list: D018033:Antibodies, Bispecific; D015703:Antigens, CD; C036832:Fc(alpha) receptor; D007070:Immunoglobulin A; D011961:Receptors, Fc